BIObank RCGP and Excess Stock of Fluad
Date sent: Tuesday 20 November 2018
All Somerset Practice Managers
We have been made aware that the attached letter is now circulating in Somerset
Biobank GDPR issues
We have been advised by the GPC that the consent form and process used by Biobank are GDPR compliant.
• The practice should be told which patients have consented and be assured that Biobank have used the current consent process.
• Unless the numbers are very small it is highly likely that, because of the unlimited nature of each patients’ disclosure, their entire record will be disclosed. Into the future a Data Privacy Impact Assessment will be necessary. These must be completed before any processing can take place.
• It is unlikely that the practice will need to report their DPIA to the ICO.
• Finally, the practice will need to give EMIS an instruction to agree to allow them to process the data; Biobank, not being the data controllers, cannot issue such an instruction
Excess stock of Fluad/aTIV (Message from Public Health)
Practices should not return any excess / unwanted Fluad (adjuvanted trivalent influenza vaccine / aTIV) supply to the manufacturer, even if they have a sale or return arrangement.
Any settings with excess stock of Fluad should contact their local CCG representative or the Public Health England South West Screening & Immunisation team ( firstname.lastname@example.org ) so that supply can be re-distributed to where it is needed in the local area.
Stock returned to the manufacturer cannot be reissued and will be destroyed resulting in a loss of vaccine within the system.
Thank you very much for your help. If you have any queries please contact your local CCG representative or the PHE Screening & Immunisation Team email@example.com
TEL: 01823 331428
We have updated our privacy policies on both the Somerset LMC and Somerset GP Education trust websites.
Attached file: Biobank.pdf